Cell Therapeutics, Inc. Focuses on Pixantrone Application in Europe, U.S. Trial and Expanded Access Program; Cuts Burn Rate

April 28, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SEATTLE, April 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (“CTI” or the “Company”) (Nasdaq and MTA: CTIC) today reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory